Olaparib shows significant progression-free survival benefit in phase III SOLO2 trial

 

Authors

  • Christian Marth AGO-Austria and Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria

DOI:

https://doi.org/10.19156/cbn.2017.0041

Abstract

No abstract available

Downloads

Published

2017-08-17

How to Cite

1.
Marth C. Olaparib shows significant progression-free survival benefit in phase III SOLO2 trial:  . CBN [Internet]. 2017 Aug. 17 [cited 2024 Nov. 23];5(2):3-4. Available from: https://journals.aboutscience.eu/index.php/cancerbreakingnews/article/view/177

Issue

Vol. 5 No. 2 (2017): August 2017

Section

Editorial

License

Articles published in Cancer Breaking News are distributed under the CC Attribution-NonCommercial-NoDerivatives 4.0 license, which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.